サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1769619

低プロトロンビン血症治療の世界市場レポート2025年

Hypoprothrombinemia Treatment Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
低プロトロンビン血症治療の世界市場レポート2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

低プロトロンビン血症治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.7％で21億2,000万米ドルに成長します。予測期間に予測される成長は、出血性疾患の有病率の増加、在宅治療に対する需要の高まり、ヘルスケアインフラの拡大、専門クリニックや血液学に特化したケアセンターの成長、個別化医療の採用の増加に起因しています。この期間の主な動向には、遺伝子組換え凝固因子、個別化医療と遺伝子プロファイリング、革新的ドラッグデリバリーシステム、ポイントオブケア診断技術、人工知能（AI）とデータ分析の統合などの進歩が含まれます。

出血性疾患の有病率の上昇は、低プロトロンビン血症治療市場の成長を促進すると予想されます。出血性疾患は、血液が適切に凝固せず、過剰な出血や長引く出血を引き起こす疾患です。このような有病率の増加は、診断方法の改善と認知度の向上によるところが大きく、そのような状態のより正確な特定と報告につながっています。低プロトロンビン血症の治療は、不足したプロトロンビン濃度を補充することで、患者の血液凝固能力を回復させるものです。例えば、英国の学術誌BMC Health Services Researchによると、英国では2022年4月から2023年3月までの間に、男性5,032人（18歳以上）、合計6,662人が血友病Aと診断され、このうち2,421人が因子補充療法またはエミシズマブによる治療を受けた。同期間中、成人1,022人を含む男性1,342人が血友病Bと記録され、そのうち479人が因子補充療法を受けた。したがって、出血性疾患の有病率の増加は、低プロトロンビン血症治療市場の拡大を促進すると予想されます。

バイオシミラーの採用拡大が低プロトロンビン血症治療市場の今後の成長を促進すると予想されます。バイオシミラーとは、すでに承認されているオリジナルの生物学的製剤と類似性が高く、安全性や有効性に大きな違いがない生物学的製剤のことです。バイオシミラー医薬品の利用が拡大している背景には、先発品の生物学的製剤と同等の安全性と有効性を維持しながら、より安価で利用しやすい治療の選択肢を提供できる可能性があることがあります。低プロトロンビン血症治療において、バイオシミラー製剤は先発品の凝固因子製剤に代わる費用対効果の高い代替療法を提供し、重要な凝固管理への患者のアクセスを向上させる。例えば、革新的な主要バイオ医薬品企業を代表する米国の業界団体であるPhRMAによれば、2022年末までに40のバイオシミラーが承認を取得し、そのうち27が米国で販売されています。このように、バイオシミラーの利用拡大が低プロトロンビン血症治療市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の低プロトロンビン血症治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の低プロトロンビン血症治療市場：成長率分析
  • 世界の低プロトロンビン血症治療市場の実績：規模と成長, 2019-2024
  • 世界の低プロトロンビン血症治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界の低プロトロンビン血症治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界の低プロトロンビン血症治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • I型欠乏症の治療
  • II型欠乏症の治療
  • 世界の低プロトロンビン血症治療市場：薬剤タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ビタミンK
  • 新鮮凍結血漿
  • プロトロンビン複合体濃縮物
  • 組換えプロトロンビン
  • 世界の低プロトロンビン血症治療市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ビタミンK欠乏症
  • 肝臓疾患
  • 肝硬変
  • 肝炎
  • 抗凝固薬関連低プロトロンビン血症
  • 遺伝性疾患
  • 吸収不良症候群
  • 世界の低プロトロンビン血症治療市場：ドラッグデリバリー方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 経口投与
  • 注射剤投与
  • 静脈内
  • 筋肉内
  • 輸血でのデリバリー
  • 世界の低プロトロンビン血症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 専門クリニック
  • 在宅ケア環境
  • 世界の低プロトロンビン血症治療市場、I型欠乏症治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • プロトロンビン複合体濃縮物（PCC）
  • 新鮮凍結血漿（FFP）
  • 組換えプロトロンビン
  • 血漿由来凝固因子
  • 世界の低プロトロンビン血症治療市場、II型欠乏症治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • ビタミンK療法
  • ワルファリン拮抗薬
  • 肝機能支持療法
  • 抗凝固療法

第7章 地域別・国別分析

  • 世界の低プロトロンビン血症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の低プロトロンビン血症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 低プロトロンビン血症治療市場：競合情勢
  • 低プロトロンビン血症治療市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Abbott
  • GlaxoSmithKline
  • Takeda Pharmaceuticals
  • Novo Nordisk A/S
  • Teva Pharmaceuticals
  • CSL Limited
  • Baxter International Inc.
  • Fresenius Kabi AG
  • Grifols S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Octapharma AG
  • Dr. Reddy's Laboratories
  • Pharmascience Inc.
  • Amphastar Pharmaceuticals Inc.
  • Pharma Cure Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 低プロトロンビン血症治療市場2029：新たな機会を提供する国
  • 低プロトロンビン血症治療市場2029：新たな機会を提供するセグメント
  • 低プロトロンビン血症治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35934

Hypoprothrombinemia treatment involves medical approaches designed to restore sufficient levels of prothrombin (Factor II), a crucial protein in blood clotting. The goal is to prevent or manage abnormal bleeding by addressing the underlying cause, which may include genetic factors, vitamin K deficiency, liver disease, or excessive use of anticoagulants.

The primary treatment types for hypoprothrombinemia are Type I and Type II deficiency treatments. Type I hypoprothrombinemia (true prothrombin deficiency) is commonly managed with prothrombin complex concentrates (PCCs) or fresh frozen plasma (FFP) to replenish prothrombin levels and enhance clotting function. Treatment options include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and recombinant prothrombin. These therapies are used for conditions such as vitamin K deficiency, liver diseases like cirrhosis and hepatitis, anticoagulant-related hypoprothrombinemia, genetic disorders, and malabsorption syndromes. Drug administration routes include oral, injectable, intravenous, intramuscular, and transfusion-based methods. The main end users are hospitals, specialty clinics, and homecare providers.

The hypoprothrombinemia treatment market research report is one of a series of new reports from The Business Research Company that provides hypoprothrombinemia treatment market statistics, including the hypoprothrombinemia treatment industry global market size, regional shares, competitors with the hypoprothrombinemia treatment market share, detailed hypoprothrombinemia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the hypoprothrombinemia treatment industry. This hypoprothrombinemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hypoprothrombinemia treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historic period can be attributed to the increasing prevalence of liver diseases, a rising incidence of malabsorption syndromes, heightened attention to coagulation disorders in critical care, greater awareness of bleeding disorders, and a surge in vitamin K deficiency cases.

The hypoprothrombinemia treatment market size is expected to see strong growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. The growth projected for the forecast period can be attributed to the increasing prevalence of bleeding disorders, rising demand for home care treatments, expansion of healthcare infrastructure, growth in specialty clinics and hematology-focused care centers, and the increasing adoption of personalized medicine. Key trends during this period include advancements in recombinant coagulation factors, personalized medicine and genetic profiling, innovative drug delivery systems, point-of-care diagnostic technologies, as well as the integration of artificial intelligence (AI) and data analytics.

The rising prevalence of bleeding disorders is expected to drive growth in the hypoprothrombinemia treatment market. Bleeding disorders are conditions where blood does not clot properly, causing excessive or prolonged bleeding. This increase in prevalence is largely due to improved diagnostic methods and greater awareness, leading to more accurate identification and reporting of such conditions. Hypoprothrombinemia treatments help restore clotting ability in patients by replenishing deficient prothrombin levels. For example, between April 2022 and March 2023 in the United Kingdom, a total of 6,662 males were diagnosed with hemophilia A, with 5,032 adults (aged 18 and above), and 2,421 of these patients received treatment through either factor replacement therapy or emicizumab, according to BMC Health Services Research, a UK-based journal. During the same period, 1,342 males were recorded with hemophilia B, including 1,022 adults, of whom 479 underwent factor replacement treatment. Therefore, the growing prevalence of bleeding disorders is anticipated to fuel the expansion of the hypoprothrombinemia treatment market.

The increasing adoption of biosimilars is expected to propel growth in the hypoprothrombinemia treatment market moving forward. Biosimilars are biologic medical products that are highly similar to an already approved original biologic, with no significant differences in safety or effectiveness. Their rising use is fueled by the potential to offer more affordable and accessible treatment options while maintaining comparable safety and efficacy to original biologics. In hypoprothrombinemia treatment, biosimilars provide cost-effective alternatives to original clotting factor therapies, enhancing patient access to vital coagulation management. For example, according to PhRMA, a US-based trade association representing leading innovative biopharmaceutical companies, by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States. Thus, the growing use of biosimilars is driving the expansion of the hypoprothrombinemia treatment market.

Leading companies in the hypoprothrombinemia treatment market are concentrating on innovative therapies like non-activated four-factor prothrombin complex concentrate (4F-PCC) to quickly restore clotting factor levels and minimize bleeding risks in patients needing urgent anticoagulation reversal. The non-activated 4F-PCC is a plasma-derived treatment that includes clotting factors II, VII, IX, and X, used to promptly counteract the effects of vitamin K antagonists and manage bleeding disorders such as hypoprothrombinemia. For example, in January 2024, Octapharma USA, a subsidiary of Octapharma AG based in the US, launched Balfaxar, a non-activated 4F-PCC recently approved by the FDA for urgent reversal of vitamin K antagonist-induced coagulation deficiencies in adults undergoing emergency surgery or invasive procedures. This therapy contains essential vitamin K-dependent clotting factors along with antithrombotic proteins, fulfilling critical needs in hypoprothrombinemia treatment.

Major players in the hypoprothrombinemia treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc, Sanofi S.A., AstraZeneca, Abbott, GlaxoSmithKline, Takeda Pharmaceuticals, Novo Nordisk A/S, Teva Pharmaceuticals, CSL Limited, Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Sun Pharmaceutical Industries Ltd., Octapharma AG, Dr. Reddy's Laboratories, Pharmascience Inc., Amphastar Pharmaceuticals Inc., Pharma Cure Laboratories.

North America was the largest region in the hypoprothrombinemia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypoprothrombinemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypoprothrombinemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypoprothrombinemia treatment market consists of revenues earned by entities by providing services such as diagnostic testing, hospital care, specialized transfusion services, therapeutic drug monitoring, and patient management programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypoprothrombinemia treatment market also includes sales of plasma-derived concentrates, synthetic clotting factors, oral anticoagulant reversal agents, blood products, and plasma derivatives. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypoprothrombinemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypoprothrombinemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hypoprothrombinemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypoprothrombinemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Type I Deficiency Treatment; Type II Deficiency Treatment
  • 2) By Drug Type: Vitamin K; Fresh Frozen Plasma; Prothrombin Complex Concentrates; Recombinant Prothrombin
  • 3) By Indication Based: Vitamin K Deficiency; Liver Diseases; Cirrhosis; Hepatitis; Anticoagulant related Hypoprothrombinemia; Genetic Disorders; Malabsorption Syndromes
  • 4) By Drug Delivery Method: Oral Delivery; Injectable Delivery; Intravenous; Intramuscular; Transfusion Based Delivery
  • 5) By End User: Hospitals; Speciality Clinics; Homecare Settings
  • Subsegment:
  • 1) By Type I Deficiency Treatment: Prothrombin Complex Concentrates (PCCs); Fresh Frozen Plasma (FFP); Recombinant Prothrombin; Plasma-derived Coagulation Factors
  • 2) By Type II Deficiency Treatment: Vitamin K Therapy; Warfarin Reversal Agents; Liver Function Supportive Therapy; Anticoagulant Adjustment Therapies
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc; Sanofi S.A.; AstraZeneca
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hypoprothrombinemia Treatment Market Characteristics

3. Hypoprothrombinemia Treatment Market Trends And Strategies

4. Hypoprothrombinemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hypoprothrombinemia Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Hypoprothrombinemia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Hypoprothrombinemia Treatment Market Growth Rate Analysis
  • 5.4. Global Hypoprothrombinemia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Hypoprothrombinemia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Hypoprothrombinemia Treatment Total Addressable Market (TAM)

6. Hypoprothrombinemia Treatment Market Segmentation

  • 6.1. Global Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Type I Deficiency Treatment
  • Type II Deficiency Treatment
  • 6.2. Global Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Vitamin K
  • Fresh Frozen Plasma
  • Prothrombin Complex Concentrates
  • Recombinant Prothrombin
  • 6.3. Global Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Vitamin K Deficiency
  • Liver Diseases
  • Cirrhosis
  • Hepatitis
  • Anticoagulant related Hypoprothrombinemia
  • Genetic Disorders
  • Malabsorption Syndromes
  • 6.4. Global Hypoprothrombinemia Treatment Market, Segmentation By Drug Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral Delivery
  • Injectable Delivery
  • Intravenous
  • Intramuscular
  • Transfusion Based Delivery
  • 6.5. Global Hypoprothrombinemia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Speciality Clinics
  • Homecare Settings
  • 6.6. Global Hypoprothrombinemia Treatment Market, Sub-Segmentation Of Type I Deficiency Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prothrombin Complex Concentrates (PCCs)
  • Fresh Frozen Plasma (FFP)
  • Recombinant Prothrombin
  • Plasma-derived Coagulation Factors
  • 6.7. Global Hypoprothrombinemia Treatment Market, Sub-Segmentation Of Type II Deficiency Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Vitamin K Therapy
  • Warfarin Reversal Agents
  • Liver Function Supportive Therapy
  • Anticoagulant Adjustment Therapies

7. Hypoprothrombinemia Treatment Market Regional And Country Analysis

  • 7.1. Global Hypoprothrombinemia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Hypoprothrombinemia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hypoprothrombinemia Treatment Market

  • 8.1. Asia-Pacific Hypoprothrombinemia Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hypoprothrombinemia Treatment Market

  • 9.1. China Hypoprothrombinemia Treatment Market Overview
  • 9.2. China Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hypoprothrombinemia Treatment Market

  • 10.1. India Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hypoprothrombinemia Treatment Market

  • 11.1. Japan Hypoprothrombinemia Treatment Market Overview
  • 11.2. Japan Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hypoprothrombinemia Treatment Market

  • 12.1. Australia Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hypoprothrombinemia Treatment Market

  • 13.1. Indonesia Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hypoprothrombinemia Treatment Market

  • 14.1. South Korea Hypoprothrombinemia Treatment Market Overview
  • 14.2. South Korea Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hypoprothrombinemia Treatment Market

  • 15.1. Western Europe Hypoprothrombinemia Treatment Market Overview
  • 15.2. Western Europe Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hypoprothrombinemia Treatment Market

  • 16.1. UK Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hypoprothrombinemia Treatment Market

  • 17.1. Germany Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hypoprothrombinemia Treatment Market

  • 18.1. France Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hypoprothrombinemia Treatment Market

  • 19.1. Italy Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hypoprothrombinemia Treatment Market

  • 20.1. Spain Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hypoprothrombinemia Treatment Market

  • 21.1. Eastern Europe Hypoprothrombinemia Treatment Market Overview
  • 21.2. Eastern Europe Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hypoprothrombinemia Treatment Market

  • 22.1. Russia Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hypoprothrombinemia Treatment Market

  • 23.1. North America Hypoprothrombinemia Treatment Market Overview
  • 23.2. North America Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hypoprothrombinemia Treatment Market

  • 24.1. USA Hypoprothrombinemia Treatment Market Overview
  • 24.2. USA Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hypoprothrombinemia Treatment Market

  • 25.1. Canada Hypoprothrombinemia Treatment Market Overview
  • 25.2. Canada Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hypoprothrombinemia Treatment Market

  • 26.1. South America Hypoprothrombinemia Treatment Market Overview
  • 26.2. South America Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hypoprothrombinemia Treatment Market

  • 27.1. Brazil Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hypoprothrombinemia Treatment Market

  • 28.1. Middle East Hypoprothrombinemia Treatment Market Overview
  • 28.2. Middle East Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hypoprothrombinemia Treatment Market

  • 29.1. Africa Hypoprothrombinemia Treatment Market Overview
  • 29.2. Africa Hypoprothrombinemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Hypoprothrombinemia Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Hypoprothrombinemia Treatment Market, Segmentation By Indication Based, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hypoprothrombinemia Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Hypoprothrombinemia Treatment Market Competitive Landscape
  • 30.2. Hypoprothrombinemia Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis

31. Hypoprothrombinemia Treatment Market Other Major And Innovative Companies

  • 31.1. Abbott
  • 31.2. GlaxoSmithKline
  • 31.3. Takeda Pharmaceuticals
  • 31.4. Novo Nordisk A/S
  • 31.5. Teva Pharmaceuticals
  • 31.6. CSL Limited
  • 31.7. Baxter International Inc.
  • 31.8. Fresenius Kabi AG
  • 31.9. Grifols S.A.
  • 31.10. Sun Pharmaceutical Industries Ltd.
  • 31.11. Octapharma AG
  • 31.12. Dr. Reddy's Laboratories
  • 31.13. Pharmascience Inc.
  • 31.14. Amphastar Pharmaceuticals Inc.
  • 31.15. Pharma Cure Laboratories

32. Global Hypoprothrombinemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypoprothrombinemia Treatment Market

34. Recent Developments In The Hypoprothrombinemia Treatment Market

35. Hypoprothrombinemia Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Hypoprothrombinemia Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Hypoprothrombinemia Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Hypoprothrombinemia Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer